Permanent J-Code for Epioxa - Summary - MDSpire
From the Journals

Permanent J-Code for Epioxa

Glaukos secures permanent J-code from CMS ahead of July rollout

  • April 22, 2026

  • 2 min

Share

Glaukos has secured a permanent HCPCS J-code (J2789) for its Epioxa therapy, which will simplify billing and reimbursement for its epithelium-on corneal cross-linking treatment for keratoconus, effective July 1, 2026. This milestone is expected to enhance payer acceptance and improve access for patients, as expressed by CEO Thomas Burns. The therapy aims to avoid epithelial removal, offering a less painful alternative and expediting recovery. Acknowledging its underdiagnosed status, Glaukos emphasizes the need for increased awareness and treatment of keratoconus.

Original Source(s)

Permanent J-Code for Epioxa

  • April 22, 2026

Related Content

AAO Updates HCQ Retinopathy Guidance

Updated recommendations emphasize dosing limits and screening for toxicity risk.

Success and Failure Rates with Increased-Range-of-Focus IOLs 

IRoF lenses offer high success, with some outperforming others

Understanding Parental Perceptions and Barriers to Myopia Control Uptake 

How risk perception, safety concerns, and practical realities shape treatment decisions